Thiolated recombinant human tumor necrosis factor-alpha protects against Plasmodium berghei K173-induced experimental cerebral malaria in mice

5Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The introduction of reactive thiol groups in recombinant human tumor necrosis factor (TNF) alpha (rhTNF-α) by the reagent succinimidyl-S- acetylthioacetate resulted in the formation of a chemically stabilized rhTNF- α trimer (rhTNFα-AT; as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis), rhTNFα-AT showed a substantially enhanced protective efficacy against the development of experimental murine cerebral malaria (ECM) after intravenous injection compared to the protective efficacy of nonmodified rhTNF-α. Administration of thiolated rhTNF-α with protected thiol groups (rhTNFα-ATA; no stabilized trimers in vitro) exhibited the same protective efficacy against ECM, while in vitro bioactivity was reduced. Parasitemia was significantly suppressed in rhTNF-treated mice that were protected against ECM but not in treated mice that developed ECM. Protection against ECM was not related to increased concentrations in plasma of soluble TNF receptor 1 and 2 directly after injection or at the moment of development of ECM in nontreated mice. The results indicate that thiolation of rhTNF-α leads to the formation of stable trimers with increased potential in vivo.

Cite

CITATION STYLE

APA

Postma, N. S., Hermsen, R. C., Crommelin, D. J. A., Eling, W. M. C., & Zuidema, J. (1999). Thiolated recombinant human tumor necrosis factor-alpha protects against Plasmodium berghei K173-induced experimental cerebral malaria in mice. Antimicrobial Agents and Chemotherapy, 43(5), 1027–1033. https://doi.org/10.1128/aac.43.5.1027

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free